Phase 1/2 Trial of 4D-710, Aerosol Gene Therapy for CF, May Soon Start
A Phase 1/2 clinical trial of an aerosol gene therapy candidate, 4D-710, in people with cystic fibrosis (CF) has been cleared by U.S. Food and Drug Administration (FDA) and is expected to start this year, its developer, 4D Molecular Therapeutics, announced. The trial is designed as an open-label, dose-escalation…